Our experimental data provide evidence that TWEAK inhibition ameliorates diabetes-driven atherosclerosis through the attenuation of STAT1 activation and proinflammatory cytokines expression, thus resulting in reduced atherosclerotic lesion development and increased plaque stability. Here, STAT1 is linked to diabetes mellitus.